Merck & Co pauses two Ph III Keytruda studies after patient deaths

Merck & Co pauses two Ph III Keytruda studies after patient deaths

Merck & Co has halted two Phase III studies examining its drug Keytruda in combination with other therapies after reports of patient deaths. Merck said it paused the trials - Keynote-183 and Keynote-185 - on the recommendation of a data monitoring committee, explaining the decision will " allow for additional information to be collected to better understand more reports of death in the Keytruda groups ."

from Biotech News